1), is currently in phase 1 development for the treatment ... quick and efficient design of the company’s CAR-T candidates in a single-step process, leading to a ‘plug-and-play ’ approach ...

Additionally, improving CAR-T biological efficiency could reduce dosing needs, further cutting costs and expanding access.

Research by Clarivate plc, BioWorld’s parent company, indicates that a notable proportion of CAR T-cell therapies in late-phase development in China are being developed through ... China grapples with ...

CRISPR drives the CAR From the outset, CRISPR looked like an ideal way to engineer a T cell. It’s a simple process, with minimal off-target effects, and works on a wide range of cell types.

‘#Bloodcancers lead the #CART revolution! #GlobalData reveals they account for over half of all CAR-T therapies in development, with 9 of the top 10 indications. #oncology’ Of the 1,729 CAR-T ...

“Rich is an enormous asset to IndyCar and the development of a new car. I don’t know who knows more about the American, if not the global, automobile industry. That’s his day job,” Miles said.